Medpace Holdings, Inc. (MEDP)

Market Cap	13.35B +58.1%
Revenue (ttm)	2.68B +24.2%
Net Income	460.40M +10.6%
EPS	15.90 +21.5%
Shares Out	28.56M
PE Ratio	29.39
Forward PE	27.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	297,217
Open	476.86
Previous Close	475.07
Day's Range	466.41 - 479.30
52-Week Range	294.07 - 628.92
Beta	1.18
Analysts	Hold
Price Target	442.83 (-5.24%)
Earnings Date	Jul 20, 2026

About MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data man...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 6,200
• Stock Exchange: NASDAQ
• Ticker Symbol: MEDP
• Website: https://www.medpace.com

Financial Performance

In 2025, Medpace Holdings's revenue was $2.53 billion, an increase of 19.97% compared to the previous year's $2.11 billion. Earnings were $451.12 million, an increase of 11.57%.

Analyst Summary

According to 13 analysts, the average rating for MEDP stock is "Hold." The 12-month stock price target is $442.83, which is a decrease of -5.24% from the latest price.

Price Target

$442.83

(-5.24% downside)

Analyst Consensus: Hold